The precise role of antiplatelet therapy in secondary stroke prevention remains a matter of some debate. Although specific antiplatelet agents (notably aspirin, ticlopidine, dipyridamole, and clopidogrel) have been shown to be active in the prevention of secondary stroke, questions remain about the effective dose of these agents and their potential efficacy in combined therapeutic regimens. In addition, haematological and gastrointestinal side-effects of antiplatelet agents remain a significant clinical concern for patients and prescribing physicians. This review article examines research on both monotherapy and combination antiplatelet therapy for secondary stroke prevention, with an emphasis on lessons learned about dosage schedules, treatment protocols, and side-effect profiles.
FieldsWS, LemakNA. FrankowskiRI. HardyRJ. Controlled trial of aspirin in cerebral ischemia. Stroke1977; 8: 301–316.
2.
SorensenPS, PedersenH. MarquardsenJ, PeterssonH, HeltbergA, SimonsenNAcetylsalicylic acid in the prevention of stroke in patients with reversible cerebral ischemic attacks. A Danish cooperative study. Stroke1983; 14: 15–22.
3.
BrittonM, HelmersC, SamuelssonK. High-dose acetylsalicylic acid after cerebral infarction. A Swedish Co-operative study. Stroke1987; 18: 325–334.
4.
SzePC, ReitmanD, PincusMM, SacksHS, ChalmersTC. Antiplatelet agents in the secondary prevention of stroke: meta-analysis of the randomized clinical trials. Stroke1988; 19: 436–442.
5.
AchesonJ, DantaG, HutchinsonEC. Controlled trial of dipyridamole in cerebral vascular disease. Br Med J1969; 1; 614–615.
6.
GentM, EastonX, HachinskiVC, PanakE, SicurellaJ, BlakelyJThe Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet1989; 2: 1215–1220.
7.
HassWKEastonDJ, AdamsHPJr, Pryce-PhillipsW, MolonyBA, AndersonS, KammB. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-disk patients. N Engl J Med1989; 321: 501–507.
8.
BousserMG, EschwegeE, HaguenauM, LefaucconnierJM, ThibultN, TouboulD, TouboulPJ. “AICLA controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke1983; 14: 5–14.
9.
Amedcan-Canadian Co-operative Study Group. Persantine aspirin trial in cerebral ischemia. Part II: endpoint results. Stroke1985; 16: 406–415.
10.
Guiraud-ChaumeilB, RascolA, DavidJ, BoneuV, ClanetM, BiertneR. Prevention des recidives des accidents vasculaires cerebraux ischemiques par les anti-agregants plaquettaires. Resultats d'un essai therapeutique control. Rev Neurol (Paris)1982; 138: 367–385.
11.
ESPS Group. The European Stroke Prevention Study (ESPS). Principal endpoints. Lancet1987; ii, 1351–1354.
12.
ESPS Group (1990). European Stroke Prevention Study (1990)Stroke1990; 21: 1123–1130.
13.
Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J1988; 296: 320–33 1.
14.
SALT Collaborative Group. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet1991; 338: 1345–1349.
15.
UK-TIA Study Group. United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psych1991; 54: 1044–54.
16.
Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med1991; 325: 1261–1266.'
17.
UK-TIA Study Group. United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: Interim results. Br Med J1988; 296: 316–320.
18.
FusterV, DykenNIL, VokonasPS, HennekensC. Aspirin as a therapeutic agent in cardiovascular disease. Circulation1993; 87: 659–675.
19.
AdamsHP, BendixenBH. Low- versus high-dose aspirin in prevention of ischemic stroke. Clin Neuropharmacol1993; 16: 485–500.
20.
Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J1994; 308: 81–106.
21.
BarnettHJM, EliasziwM, MeldrumHE (1995) Drugs and surgery in the prevention of ischemic stroke. N Engl J Med1995; 332: 238–248.
22.
AlgraA, van GijnJ. Aspirin at any.dose above 30 mg offers only modest protection after cerebral ischaemia. JNeurol Neurosurg Psychiatry1996; 60: 197–199.
23.
DienerHC, CunhaL, ForbesC, SiveniusJ, SmetsP, LowenthalA. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci1996; 143: 1–13.
24.
MullerTH, SuCAPF, WeisenbergerH, BricklR, NehmizG, EisertWG. Dipyridamole alone or combined with low-dose acetylsalicylic acid inhibits platelet aggregation in human whole blood ex vivo. Br J Clin Pharmacol1990; 30: 179–186.
25.
ESPS 2 Group. European Stroke Prevention Study 2: Efficacy and safety data. J. Neurological Sci1997; 151 (suppl): S1–S78.
26.
CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet1996; 348: 1329–1339.
